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Abstract 
There is lack of consensus about the significance and management of an incidental finding of 
endometrial thickness (ET) >4mm on transvaginal ultrasound scan in postmenopausal women 
without postmenopausal bleeding (PMB). The data of 1995 consecutive women attending PMB 
clinic were collected prospectively; of them 81 (4.1%) were referred because of ET>4mm 
without PMB. The prevalence of endometrial atypical hyperplasia and cancer was 4/81 (4.9%) 
and polyp was 20/81 (24.7%). On using Receiver Operator Characteristic curve, the diagnosis of 
endometrial atypical hyperplasia and cancer using ET threshold of ≥10mm had sensitivity of 
100% (95% CI=40-100%), specificity of 60% (95% CI=48-71%) with AUC=0.8 (95% CI=0.66-
0.93), p<0.04. For the 35 women with ET ≥10mm, the prevalence of endometrial atypical 
hyperplasia and cancer was 4/35 (11.4%) and benign endometrial polyps was 16/35 (45.7%). The 
use of ≥10mm ET threshold to prompt investigations did not miss any case of endometrial 
atypical hyperplasia or cancer. 
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Impact statement: 
What is already known about this topic: 
Unlike women with PMB in whom endometrial thickness (ET) ≤4mm is considered as low risk 
for endometrial hyperplasia and cancer, in postmenopausal women without PMB, the threshold 
that separates normal from pathologically thickened endometrium has not been standardized. A 
decision-analysis study in a hypothetical cohort found that ET threshold of 11mm yields a 
similar separation as ≤4mm in those with PMB. 
What does this paper add? 
The study uses prospectively collected data from consecutive patients using standardized format, 
thus minimizing bias from incomplete data. This study is the third prospective series in the 
literature to address the dilemma of management of asymptomatic postmenopausal women with 
incidental finding of thickened endometrium. It showed that the prevalence of endometrial 
atypical hyperplasia and cancer is high enough to justify investigation and for the clinical 
problem not to be trivialized. All cases of endometrial atypical hyperplasia and cancer had 
endometrial thickness of ≥10mm. 
Clinical implications and future research: 
Our data strengthen the current body of literature to help development of clinical practice 
guidelines about the management work-up. However, a well-designed multi-centre large 
prospective study is required to confirm the findings since most studies in the literature are either 
retrospective or small. 
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Introduction 
Trans-vaginal ultrasound scan (TVS) is frequently performed in postmenopausal women referred 
for a variety of symptoms, such as pelvic pain or bloating. Although concerns regarding 
endometrial pathology may not have been the indication for the test, endometrial thickness (ET) 
is often measured. The incidental finding of ET> 4mm in the absence of postmenopausal 
bleeding (PMB) is a common cause of referral to secondary care, and can lead to a cascade of 
interventions to exclude endometrial hyperplasia or cancer (Jade et al., 2016). There is lack of 
consensus amongst gynecologists about its significance, and there are no evidence-based 
guidelines to inform clinical practice as how these women are best managed, leading to wide 
variations in practice (Gambacciani et al., 2004, Giannella et al., 2014). 
 
Ninety percent of women with endometrial cancer present with PMB, and women with PMB 
have a 5-10% chance of having endometrial cancer (Bachmann et al., 2003, ACOG, 2009). 
However; it is estimated that up to 15% of endometrial cancers occur in women without PMB 
(NIH National Cancer Institute, 2000). It is well established that ET ≤4mm in women with PMB 
is associated <1% risk of endometrial cancer; therefore, these women are usually reassured 
without the need for further investigations (ACOG, 2009, RCOG, 2016). However; in 
postmenopausal women without PMB, the threshold that separates normal from pathologically 
thickened endometrium has not been standardized. Smith-Bindman et al performed a decision 
analysis study, in a theoretical cohort of 10 000 postmenopausal women aged ≥ 50 years using 
published and unpublished data, to determine the ET threshold that should be considered 
abnormal in asymptomatic postmenopausal women. They found that in a postmenopausal 
woman with PMB, the risk of endometrial cancer is approximately 0.07% if the endometrium is 
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thin (≤5 mm) and 7.3% if her endometrium is thick (>5mm). In a postmenopausal woman 
without PMB, an 11mm threshold yields a similar separation between women who are at high 
risk and low risk for endometrial cancer. The risk of cancer is approximately 0.002% if the 
endometrium is thin (≤11 mm) and 6.7% if the endometrium is thick (>11 mm). If an ET 
threshold of 4 mm was used to define an abnormal test result, as in women with PMB, the 
number of false-positive test results would far outnumber the true-positive test results (Smith-
Bindman et al., 2004). 
 
In addition, two previous studies found that endometrial polyps are the commonest pathology 
encountered in postmenopausal women with asymptomatic increase in ET. The reported 
prevalence varied between 34%-73%, and hysteroscopy was recommended as the first line 
investigation tool (Farfaras et al., 2011, Schmidt et al., 2009).  
 
Given the current controversy surrounding the significance and management of thickened 
endometrium of >4mm in postmenopausal women without PMB, this study was conducted to (1) 
quantify the prevalence of endometrial hyperplasia, cancer and polyps, (2) determine the 
optimum ET threshold that should be considered abnormal and trigger further investigations. The 
aim was to produce data to help the development of clinical practice guidelines about the 
management work-up. 
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Materials and methods 
The routine demographic and clinical data of the PMB clinic was collected prospectively in a 
password-protected Microsoft Access database, and then was extracted anonymously and 
compiled on a Microsoft Excel spreadsheet (Microsoft corporation 2010, Redmond, WA, USA). 
The database contained the details of 1995 consecutive women referred to Sandwell and West 
Birmingham Hospitals NHS Trust, West Midlands, UK between 1st January 2011 and 31st 
January 2015. The study group included 81 (4.1%) postmenopausal women with incidental 
finding of ET >4mm in the absence of PMB. 
 
The TVS and histopathology reports were accessed using the electronic Clinical Data Archive 
(CDA, 2007) System that was developed by the IT department of the Trust as a repository of 
patients’ administrative and clinical data. The case notes were reviewed for women undergoing 
hysteroscopic (diagnostic or therapeutic) procedure to obtain the operation findings. 
 
All postmenopausal women with incidental finding of ET >4mm without PMB were offered 
Pipelle endometrial biopsy. However, the decision to perform hysteroscopy was individualized 
after the discussion between the patient and consultant. Women were categorized according to 
the investigation results into: (i) Group 1: benign endometrium (including benign endometrial 
polyps), and (ii) Group 2: endometrial atypical hyperplasia and cancer. Endometrial atypical 
hyperplasia and cancer were combined as a single disease. This is because of the high rate of 
undercall and progression to cancer when atypical hyperplasia is found (Smith et al., 2014, 
Gallos et al., 2013). 
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Statistical analysis 
Statistical analyses were carried out using IBM
®
 SPSS
®
 Statistics for windows software version 
20 (International Business Machines (IBM) corporation, Armonk, NYC, USA). Continuous 
variable indices are presented as mean with standard deviation or as median with inter-quartile 
range (IQR) as distribution demands. 
 
Receiver operator characteristic (ROC) curve was used to identify the ET cut-off point for 
pathological endometrium. From the ROC curve, we calculated the area under the curve (AUC) 
with 95% confidence interval (95%CI), p value, sensitivity and specificity for the relevant cut-
off point. The following equation was used to define the optimum cut-off point (Indrayan, 2013): 
(1 − 	
	) + (1 − 	) 
 
Fisher’s Exact test was used to find the statistical association between the ET cut-off point and 
the outcome.  
 
Data were collected as part of the routine investigations and treatment, and the project was 
considered as "service evaluation"; therefore, ethics approval was not deemed necessary. Service 
evaluation may not require ethical approval in the UK (NHS Health Research Authority, 2011, 
UCL Research Ethics Committe 2015). 
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Results 
The prevalence of endometrial atypical hyperplasia and cancer was 4/81 (4.9%) and benign 
endometrial polyps was 20/81 (24.7%) in postmenopausal women with incidental finding of ET 
>4mm without PMB. Women’s characteristics and investigations findings are shown in table 1 
and table 2, respectively. Three women were diagnosed with endometrial cancer. The first was 
86-year-old, body mass index (BMI) was not measured as she was wheel-chair dependent, and 
the ET was 25mm. The second was 75-year-old, BMI was 26, and the ET was 12mm. The third 
was 83-year-old, BMI was 26, and the ET was 10mm. One woman was diagnosed with 
endometrial atypical hyperplasia who was 57-year-old, BMI was 33, and the ET was 16mm. 
None of these four women was a user of HRT or Tamoxifen. 
 
The ROC curve (Figure 1) identified the ET threshold for diagnosing endometrial atypical 
hyperplasia and cancer as ≥10mm with sensitivity of 100% (95% CI=40-100%), specificity of 
60% (95% CI=48-71%), AUC=0.8 (95% CI=0.66-0.93), p<0.04. 
 
The outcome of investigations using ≥10mm endometrial thickness threshold is summarized in 
table 3. The prevalence of endometrial atypical hyperplasia and cancer was significantly high 
with ET ≥10mm, p=0.03. For the 35 women with ET ≥10mm, the prevalence of endometrial 
atypical hyperplasia and cancer was 4/35 (11.4%) and benign endometrial polyps was 16/35 
(45.7%). 
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Discussion 
To our knowledge, this is the third prospective study to address the dilemma of management of 
postmenopausal women referred to secondary care with thickened endometrium without PMB. 
The prevalence of endometrial atypical hyperplasia and cancer was 4.9% and benign endometrial 
polyps was 24.7%. The ROC curve identified the ET cut-off level for endometrial atypical 
hyperplasia and cancer to be ≥10mm.  
 
In their prospective series, Schmidt et al reported similar prevalence of endometrial atypical 
hyperplasia and cancer (4.9%), but higher prevalence of endometrial polyps (73.3%) (Schmidt et 
al., 2009), while Giannella et al found the prevalence to be 2.1% and 34%, respectively 
(Giannella et al., 2014). The other three published series in the past decade were retrospective 
carrying the risk of bias from heterogeneity and missing data. They reported wide variations in 
the prevalence of endometrial atypical hyperplasia and cancer (1.3%-13.2%) and endometrial 
polyps (27.2%-59.1%) (Famuyide et al., 2014, Saatli et al., 2014, Yasa et al., 2016). In 
particular, the high prevalence of endometrial atypical hyperplasia and cancer (70/530, 13.2%) in 
Saatli et al study is hard to explain since it is much higher than the reported prevalence of the 
disease in women with PMB which varied in the literature between 5-10% (ACOG, 2009, 
Bachmann et al., 2003). 
 
Ninety percent of women with endometrial cancer present with PMB as previously mentioned. 
(Bachmann et al., 2003, ACOG, 2009). Nonetheless, there is likely a preclinical phase during 
which some cancers might be detectable prior to the development of symptoms. In addition, 
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some cancers do not present with bleeding until they progressed beyond Stage I (Smith et al., 
2014). The National Institute for Health and Care Excellence (NICE) sets a 3% positive 
predictive value to trigger referrals to secondary care for investigations for suspected cancer 
(NICE, 2015). In this study, the endometrial atypical hyperplasia and cancer prevalence of 
11.4% indicates that referral of postmenopausal women with incidental finding of thickened 
endometrium ≥10mm is warranted. 
 
Giannella et al tested the diagnostic accuracy of various ET cut-off values by comparing 
histological and hysteroscopic findings in asymptomatic postmenopausal women with ET>4mm. 
They found that no ET cut-off values had optimal diagnostic accuracy, but an ET cut-off value 
>10 mm did not miss any cases of endometrial atypical hyperplasia or cancer. At this cut-off 
value, the atypical hyperplasia and cancer rate was 9.4%. On using ET cut-off value >4 mm, 
97% of performed hysteroscopies revealed a benign intra-uterine pathology (Giannella et al., 
2014). Smith-Bindman et al concluded after the decision-analysis study that no cut-off is perfect, 
and cancer will be missed no matter what cut-off is used. However, using a threshold of 11 mm 
seems to provide an acceptable trade-off between cancer detection and unnecessary biopsies 
prompted by an incidental finding (Smith-Bindman et al., 2004). In this study, the ≥10mm 
threshold identified by the ROC curve had sensitivity of 100%, which would be more reassuring 
to clinicians than 11mm cut-off. 
 
Our data strengthens the current body of literature to help development of clinical practice 
guidelines about the management work-up. The data were collected prospectively, consecutively, 
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and in a standardized fashion, minimizing bias from incomplete data. We included a 
homogeneous cohort of postmenopausal women referred to secondary care with incidental 
finding of ET >4mm without PMB. Nonetheless, given the small sample size, we could not 
include in the analysis women’s characteristics and risk factors for endometrial hyperplasia and 
cancer such as age and body mass index. 
 
A well-designed multi-center large prospective study is required to reach consensus about the 
optimum ET cut-off to initiate investigation in asymptomatic postmenopausal women with 
incidental finding of thickened endometrium. This study showed that the prevalence of 
pathology is high enough to justify investigation and for the clinical problem not to be trivialized 
by women and doctors alike. The use of ≥10mm ET threshold to prompt investigations may be 
acceptable since it is unlikely to miss endometrial atypical hyperplasia or cancer. 
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Tables and figures legends 
Table 1: Characteristics of postmenopausal women referred with incidental finding of ET >4mm 
without PMB (n=81) 
Table 2: Investigations findings of postmenopausal women referred with incidental finding of 
ET >4mm without PMB (n=81) 
Table 3: The outcome of investigations using ≥10mm endometrial thickness threshold 
Figure 1: Endometrial thickness receiver operator characteristic (ROC) curve for endometrial 
atypical hyperplasia and cancer. Arrow indicates the point where the 10mm endometrial 
thickness lies on the curve; Area under the curve (AUC) for the endometrial thickness cut-off 
≥10mm is 0.8, 95% confidence interval (CI)=0.66-0.93, p=0.04, sensitivity = 100% (95% CI=40-
100%), specificity = 60% (95% CI=48-71%) 
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Table 1: Characteristics of postmenopausal women referred with incidental finding of ET >4mm without PMB (n=81) 
Variable  
Age in years, mean (±SD) 68.2 (9.8) 
LMP in years, mean (±SD) 15 (6.4) 
BMI, median (IQR) 29 (8) 
HRT users 
Yes, n (%) 
No, n (%) 
 
5 (6.2%) 
76 (93.8%) 
Tamoxifen users 
Yes, n (%) 
No, n (%) 
 
6 (7.4%) 
75 (92.6%) 
BMI=Body mass index     ET=Endometrial thickness 
HRT=Hormonal replacement therapy   LMP=Last menstrual period 
IQR=Interquartile range     SD=Standard deviation 
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Table 2: Investigations findings of postmenopausal women referred with incidental finding of ET >4mm without PMB (n=81) 
Variable  
ET in mm, mean (±SD) 10.3 (6.3) 
Benign endometrium, n (%) 77 (95.1%) 
Endometrium with no hyperplasia or cancer, n (%) 57 (70.4%) 
Benign endometrial polyp, n (%, 95%CI) 20 (24.7%, 16-35.7%) 
Atypical endometrial hyperplasia and cancer, n (%, 95%CI) 4 (4.9%, 1.6-13%) 
ET=endometrial thickness 
CI=confidence interval 
SD=standard deviation 
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Table 3: The outcome of investigations using ≥10mm endometrial thickness threshold 
Variable ET ≥10mm ET <10mm p value 
 n (%) n (%)  
Benign endometrium     
Endometrium with no hyperplasia or cancer 15 (42.9%) 42 (91.3%)  
Benign endometrial polyp 16 (45.7%) 4 (8.7%)  
Endometrial atypical hyperplasia and cancer 4 (11.4%) 0 0.03* 
Total 35 46  
ET=endometrial thickness 
CI=confidence interval 
*p is measured by Fisher’s Exact test and considered significant when <0.05 
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Endometrial thickness receiver operator characteristic (ROC) curve for endometrial atypical hyperplasia and 
cancer. Arrow indicates the point where the 10mm endometrial thickness lies on the curve; Area under the 
curve (AUC) for the endometrial thickness cut-off ≥10mm is 0.8, 95% confidence interval (CI)=0.66-0.93, 
p=0.04, sensitivity = 100% (95% CI=40-100%), specificity = 60% (95% CI=48-71%)  
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